PolyGene Secures Angel Funding Led by Shoufa Development Venture Capital with Siquence as Exclusive Financial Advisor

Recently, Beijing PolyGene Bio Technology Co., Ltd. (PolyGene, hereinafter referred to as “PolyGene Bio”) announced the completion of its angel financing round. This round of financing was led by BeijingCapital Science and Technology Development Group Investment Management Co., Ltd.（(hereinafter referred to as “Shoufa Zhan Venture Capital”) through exclusive investment.SiquenceServed as the exclusive financial advisor in this transaction.

This round of financing will be primarily used to advance the upgrade of PolyGene Bio’s core technology platform and the construction of its domestic GMP manufacturing center. The company will concentrate resources on overcoming technical challenges to achieve process scale-up for single-batch suspension cell transfection at the thousand-liter level, while further recruiting top-tier interdisciplinary talent to comprehensively accelerate the commercial deployment and industrial translation of cutting-edge technologies in the biopharmaceutical sector.

PolyGene Bio is a high-tech enterprise focused on upstream core materials for cell and gene therapy (CGT) and gene transfection reagents. Leveraging its globally first-of-its-kindHyperbranched Poly(β-amino Ester) (HPAE) Macromolecular Gene Delivery Technology Platform,Dedicated to addressing the longstanding challenge of balancing transfection efficiency with cytotoxicity in traditional non-viral transfection reagents (such as liposomes and PEI), and to breaking the monopoly held by European and American companies on high-end core transfection reagents in China, a critical bottleneck for the domestic industry.

Currently, PolyGene Bio has already inBreakthroughs Achieved in Multi-Monomer Controlled Polymerization Technology and Delivery System Adaptation Design for “A2+B4+C2” and “A2+B3+C2”. Compared with traditional PEI-based materials that have long dominated the field, PolyGene Bio’s HPAE gene delivery vector not only demonstrates transfection efficiency several times higher than that of conventional reagents, but also exhibits extremely low cytotoxicity and excellent biodegradability.This technology effectively accommodates various nucleic acids and gene-editing tools, including DNA, mRNA, siRNA, and RNPs. It significantly reduces reagent consumption in industrial-scale processes and lowers the difficulty of downstream purification, thereby providing a critically scarce core foundational capability that supports the self-reliance and controllability of China’s cell and gene therapy (CGT) industry.

PolyGene Bio Founding Team“Safe and efficient gene delivery solutions are the ‘Achilles’ heel’ of the modern biomedical industry. For many years, our team has been dedicated to seeking breakthroughs in fundamental materials science. The success of the HPAE technology platform not only comprehensively surpasses traditional non-viral vectors, which have long struggled to balance transfection efficiency with safety, but also marks a significant milestone in our translation of cutting-edge polymer science into industrial-grade solutions. This round of financing will greatly accelerate the development of our domestic GMP mass production system. PolyGene Bio is committed to providing the global life sciences industry with superior, fully autonomous, and controllable core delivery platforms.”

Shoufa Zhenchuang Venture Capital Investment Team“Life sciences constitute a vital pillar of China’s national strategic emerging industries, while foundational core materials and delivery technologies serve as the critical bedrock determining the overall development trajectory of the cell and gene therapy (CGT) sector. In the field of hyperbranched polymer-based gene delivery, PolyGene Bio has not only overcome the limitations of traditional technical approaches but also demonstrated significant technological barriers and scalable mass-production potential in achieving domestic substitution for high-end transfection reagents. CapitalBio Development has always shouldered the mission of facilitating the commercialization of cutting-edge scientific achievements in Beijing, maintaining a strong focus on hard-tech enterprises with disruptive innovation capabilities. Through this investment, we look forward to fully leveraging CapitalBio Development’s industrial ecosystem resources to deeply empower PolyGene Bio, accelerating its critical leap from breakthroughs in frontier technologies to industrial-scale commercialization, thereby truly resolving the ‘chokepoint’ challenges associated with core upstream raw materials in the industry.”

Mr. Jin Pingyu, Executive Director of XiXu“Identifying and serving true innovators is the core vision of Xixu. We recognize the disruptive potential of PolyGene Bio’s foundational delivery technologies, and we are honored to partner with such a passionate team of scientist-entrepreneurs. For Xixu, financing services entail more than just capital matchmaking; they represent a commitment to long-termism. We are dedicated to helping companies solidify their operational foundations at early stages, evolving from pure transaction advisors to co-cultivators of intrinsic corporate value. We look forward to PolyGene Bio accelerating the impact of its technological innovations with the support of its first development round.”

PolyGene Bio is an innovative biotechnology company co-founded by a team of scientists including a Chair Professor under the “Chang Jiang Scholars Program,” Tsinghua University alumni, and returnees from University College Dublin. Leveraging its proprietary HPAE controlled polymerization technology, the company provides efficient, precise, and safe system-level gene delivery solutions to R&D and manufacturing enterprises in cell and gene therapy (CGT), companies specializing in transient transfection production of recombinant proteins/pseudoviruses, as well as leading research institutions.

Shoufazhan Venture Capital, a market-oriented fund management and operation platform led by the Shoufazhan team, adheres to the mature and effective investment service philosophy for original innovative technologies of Shoufazhan Group. It undertakes the group’s mission of market-oriented sci-tech investment in original innovations, focusing on groundbreaking and disruptive scientific and technological achievements in key fields such as life sciences, electronic information, and new materials. Through direct or indirect equity investments, it accelerates the externalization and commercialization of these achievements. Currently, Shoufazhan Venture Capital manages 12 funds and has facilitated the landing in Beijing of over 30 high-quality projects translating technologically advanced research outcomes from institutions such as Tsinghua University, Peking University, and the Chinese Academy of Sciences.

Siquence is an emerging boutique investment bank and consulting firm, specializing in providing financing advisory, financial compliance upgrades, and strategic consulting services to early-stage companies in hard-tech sectors such as life sciences and AI.